Journal Mobile Options
Table of Contents
Vol. 23, No. 3, 2007
Issue release date: February 2007
Section title: Original Research Article
Dement Geriatr Cogn Disord 2007;23:161–167
(DOI:10.1159/000098335)

Effects of Donepezil on Central Processing Speed and Attentional Measures in Parkinson’s Disease with Dementia and Dementia with Lewy Bodies

Rowan E. · McKeith I.G. · Saxby B.K. · O’Brien J.T. · Burn D. · Mosimann U. · Newby J. · Daniel S. · Sanders J. · Wesnes K.
aInstitute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, bCognitive Drug Research Ltd., CDR House, Goring-on-Thames, UK

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Received: 4/11/2006
Accepted: 6/21/2006
Published online: 12/28/2006

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 1

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: http://www.karger.com/DEM

Abstract

Background: We examined attention-enhancing effects of the cholinesterase inhibitor donepezil in Dementia with Lewy bodies (DLB) and Parkinson’s disease with dementia (PDD) by means of open label study. Methods: 22 DLBs and 23 PDDs were assessed over 20 weeks using the Cognitive Drug Research Computerized Attentional Tasks. We examined how much closer our patients moved towards being normal for their age by comparing them to a non-demented elderly control sample (n = 183, aged 71–75 years). Results: Donepezil treatment improved power of attention, continuity of attention and reaction time variability. The deficit in responses was moved towards normal by 38 and 56% for power of attention and 22 and 10% for continuity of attention in PDD and DLB, respectively. Conclusions: Improvements in attention were found with donepezil in PDD and DLB.


  

Author Contacts

Ian G. McKeith
Institute for Ageing and Health
Newcastle General Hospital, Westgate Road
Newcastle upon Tyne, NE4 6BE (UK)
Tel. +44 191 256 3018, Fax +44 191 219 5071, E-Mail i.g.mckeith@ncl.ac.uk

  

Article Information

Published online: December 28, 2006
Number of Print Pages : 7
Number of Figures : 1, Number of Tables : 1, Number of References : 22

  

Publication Details

Dementia and Geriatric Cognitive Disorders

Vol. 23, No. 3, Year 2007 (Cover Date: February 2007)

Journal Editor: Chan-Palay, V. (New York, N.Y.)
ISSN: 1420–8008 (print), 1421–9824 (Online)

For additional information: http://www.karger.com/DEM


Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Received: 4/11/2006
Accepted: 6/21/2006
Published online: 12/28/2006

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 1

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: http://www.karger.com/DEM


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.